Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment

Li, Ruixiang; He, Yuwei; Zhang, Shuya; Qin, Jing; Wang, Jianxin

doi:10.1016/j.apsb.2017.11.009

Cited by 303 publications

(203 citation statements)

References 82 publications

Supporting

Mentioning

197

Contrasting

Unclassified

Order By: Relevance

“…The vital organs including the heart, liver, spleen, lung, and kidney were obtained after three weeks. In line with the nontoxicity of CMBNPs [19], there were no pathological changes in the tissue revealed by haematoxylin and eosin (HE) staining ( Fig. 3c), indicative of the biocompatibility of PINPs@PM in vivo.…”

Section: In Vitro and In Vivo Toxicological Evaluationsupporting

confidence: 61%

Irradiation pretreatment enhances the therapeutic efficacy of platelet-membrane-camouflaged antitumor nanoparticles

Chen

Shen

Han

et al. 2020

Preprint

View full text Add to dashboard Cite

Backgroud: Cell membrane-based nanocarriers are promising candidates for delivering antitumor agents. The employment of a simple and feasible method to improve the tumor-targeting abilities of these systems is appealing for further application. Herein, we prepared a platelet membrane (PM)-camouflaged antitumor nanoparticle. The effects of irradiation pretreatment on tumor targeting of the nanomaterial and on its antitumor action were evaluated. Results: The biomimetic nanomaterial constructed by indocyanine green, poly(d,l-lactide-co-glycolide), and PM is termed PINPs@PM. A 4-Gy X-ray irradiation increased the proportions of G2/M phase and Caveolin-1 content in 4T1 breast cancer cells, contributing to an endocytic enhancement of PINPs@PM. PINPs@PM produced hyperthermia and reactive oxygen species upon excitation by near-infrared irradiation, which were detrimental to the cytoplasmic lysosome and resulted in cell death. Irradiation pretreatment thus strengthened the antitumor activity of PINPs@PM in vitro. Mice experiments revealed that irradiation enhanced the tumor targeting capability of PINPs@PM in vivo. When the same dose of PINPs@PM was intravenously administered, irradiated mice had a better outcome than did mice without X-ray pretreatment. Conclusion: The study demonstrates an effective strategy combining irradiation pretreatment and PM camouflage to deliver antitumor nanoparticles, which may be instrumental for targeted tumor therapy.

show abstract

Section: In Vitro and In Vivo Toxicological Evaluationsupporting

confidence: 61%

Irradiation pretreatment enhances the therapeutic efficacy of platelet-membrane-camouflaged antitumor nanoparticles

Chen

Shen

Han

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…The use of cancer cell plasma membranes has attracted attention because these membranes carry tumor-specific receptors and antigens that play a role in cancer cell proliferation, invasion, and metastasis. While several comprehensive reviews have summarized the applications of cell membrane camouflaged NPs (34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44)(45)(46) from various cell sources, to the best of our knowledge only one of these reviews is focused on advances with CCMCNPs (37).…”

Section: Introductionmentioning

confidence: 99%

Biomimetic Nanoparticles Camouflaged in Cancer Cell Membranes and Their Applications in Cancer Theranostics

Jin

Bhujwalla

2020

Front. Oncol.

View full text Add to dashboard Cite

Nanoparticles (NPs) camouflaged in cell membranes represent novel biomimetic platforms that can mimic some of the membrane functions of the cells from which these membranes are derived, in biological systems. Studies using cell membrane coated NPs cover a large repertoire of membranes derived from cells such as red blood cells, immune cells, macrophages, and cancer cells. Cancer cell membrane coated nanoparticles (CCMCNPs) typically consist of a NP core with a cancer cell plasma membrane coat that can carry tumor-specific receptors and antigens for cancer targeting. The NP core can serve as a vehicle to carry imaging and therapeutic moieties. As a result, these CCMCNPs are being investigated for multiple purposes including cancer theranostics. Here we have discussed the key steps and major issues in the synthesis and characterization of CCMCNPs. We have highlighted the homologous binding mechanisms of CCMCNPs that are being investigated for cancer targeting, and have presented our data that identify BT474 CCMCNPs as binding to multiple cancer cell lines. Current preclinical applications of CCMCNPs for cancer theranostics and their advantages and limitations are discussed.

show abstract

“…Finally, throughout this complicated journey, nanoparticles should evade their capture by immune cells, which are finely trained to recognize all types of exogenous bodies, as is the case of nanoparticles. Many efforts have been devoted to avoiding immune nanoparticle capture, from the surface decoration with hydrophilic polymers as polyethylene glycol (PEG) [21], to the use of biological membranes of red blood cells [22] or leukocytes as camouflage against the immune system surveillance [23]. Despite these efforts, a significant extent of the injected nanoparticles ends cleared by immune cells, which reduces the amount of them that reach tumoral cells.…”

Section: Introductionmentioning

confidence: 99%

Tumor Targeted Nanocarriers for Immunotherapy

Baeza

2020

Molecules

View full text Add to dashboard Cite

The paramount discovery of passive accumulation of nanoparticles in tumoral tissues triggered the development of a wide number of different nanoparticles capable of transporting therapeutic agents to tumoral tissues in a controlled and selective way. These nanocarriers have been endowed with important capacities such as stimuli-responsive properties, targeting abilities, or the capacity to be monitored by imaging techniques. However, after decades of intense research efforts, only a few nanomedicines have reached the market. The reasons for this disappointing outcome are varied, from the high tumor-type dependence of enhanced permeation and retention (EPR) effect to the poor penetration capacity of nanocarriers within the cancerous tissue, among others. The rapid nanoparticle clearance by immune cells, considered another important barrier, which compromises the efficacy of nanomedicines, would become an important ally in the fight against cancer. In the last years, the fine-tuned ability of immune cells to recognize and engulf nanoparticles have been exploited to deliver immunoregulating agents to specific immune cell populations selectively. In this work, the recent advances carried out in the development of nanocarriers capable of operating with immune and tumoral cells in order to orchestrate an efficient antitumoral response will be presented. The combination of nanoparticles and immunotherapy would deliver powerful weapons to the clinicians that offer safer and more efficient antitumoral treatments for the patients.

show abstract

Cell membrane-based nanoparticles: a new biomimetic platform for tumor diagnosis and treatment

Cited by 303 publications

References 82 publications

Irradiation pretreatment enhances the therapeutic efficacy of platelet-membrane-camouflaged antitumor nanoparticles

Irradiation pretreatment enhances the therapeutic efficacy of platelet-membrane-camouflaged antitumor nanoparticles

Biomimetic Nanoparticles Camouflaged in Cancer Cell Membranes and Their Applications in Cancer Theranostics

Tumor Targeted Nanocarriers for Immunotherapy

Contact Info

Product

Resources

About